论文部分内容阅读
目的探讨化疗对合并2型糖尿病(T2DM)恶性肿瘤患者血清白细胞介素-6(IL-6)水平的影响。方法选择合并T2DM恶性肿瘤患者40例,非合并T2DM恶性肿瘤患者40例,两组患者均给予2个周期化疗,并采集每周期化疗前1 d和化疗结束后第2天空腹静脉血,分离血清,采用酶联免疫吸附法(ELISA)检测血清IL-6含量,并选取20例健康人群进行对照比较。结果第1周期化疗前合并/非合并T2DM组IL-6含量均明显高于正常对照组(P<0.05)。合并T2DM组不同类型肿瘤患者第1周期化疗后血清IL-6含量降低,而第2周期化疗后含量却较第2周期化疗前升高(P<0.05);非合并T2DM组不同类型肿瘤患者第1、2周期化疗后血清IL-6含量呈持续降低趋势(P<0.05),但两组间比较差异无统计学意义(P>0.05)。结论第1周期化疗可促进合并/非合并T2DM恶性肿瘤患者血清IL-6表达水平下降;第2周期化疗可继续促进非合并T2DM恶性肿瘤患者血清IL-6表达水平下降,但却同时促进合并T2DM恶性肿瘤患者血清IL-6表达水平回升。
Objective To investigate the effect of chemotherapy on the serum level of interleukin-6 (IL-6) in patients with type 2 diabetes mellitus (T2DM). Methods Forty patients with T2DM and 40 patients without T2DM were enrolled in this study. Two cycles of chemotherapy were given to both groups, and the fasting venous blood was collected on the first day before chemotherapy and on the second day after chemotherapy, respectively Serum IL-6 levels were measured by enzyme-linked immunosorbent assay (ELISA), and 20 healthy people were selected for comparison. Results The level of IL-6 in the first cycle chemotherapy combined with / without T2DM group was significantly higher than that in the normal control group (P <0.05). The levels of IL-6 in serum of patients with different types of T2DM combined with chemotherapy after the first cycle were lower than those before chemotherapy in the second cycle (P <0.05) The levels of IL-6 in the serum of patients with chronic bronchitis were continuously decreased after 1 and 2 cycles of chemotherapy (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusions The first cycle chemotherapy can promote the decrease of serum IL-6 level in T2DM patients with T2DM. The second cycle chemotherapy can continue to promote the decrease of serum IL-6 level in T2DM patients with non-T2DM malignancy, Patients with malignant tumor serum IL-6 expression levels rise.